CelLBxHealth
CelLBxHealth plc is a UK-based liquid biopsy company that develops the Parsortix microfluidic platform for label-free isolation and molecular analysis of circulating tumor cells (CTCs), serving pharmaceutical drug discovery, diagnostic development, and translational research customers through instrument sales and laboratory services.
- Company typePublic
- Founded2006
- HeadquartersGuildford, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What CelLBxHealth does
CelLBxHealth plc (formerly ANGLE plc, rebranded December 2025) is a UK-based liquid biopsy company specializing in the capture and molecular analysis of circulating tumor cells (CTCs). The company's core technology is the Parsortix platform, a patented label-free microfluidic system that enriches and recovers viable CTCs and CTC clusters from whole blood using a single-use cassette that isolates cells based on size and deformability. Unlike marker-dependent antibody methods, Parsortix captures a broad range of phenotypes including mesenchymal and EMT-transitioning cells, enabling downstream applications such as biomarker assessment, therapy selection, resistance monitoring, and tumor evolution studies. The platform is complemented by the CellKeep Slide harvesting technology, the Portrait+ CTC Staining Kit, and a comprehensive menu of laboratory services including CTC enumeration, immunofluorescence assays for PD-L1, HER2, androgen receptor, and DDR biomarkers, plus molecular assays for gene expression profiling and next-generation sequencing.
The company serves three primary customer segments: (1) pharmaceutical and biopharmaceutical companies requiring CTC analysis for drug discovery, clinical trial sample analysis, and companion diagnostic development; (2) diagnostic companies integrating CTC technology into molecular diagnostic workflows; and (3) contract research organizations, academic medical centers, and healthcare providers conducting translational and clinical research. CelLBxHealth monetizes through three revenue streams: pharmaceutical and laboratory services (fee-for-service custom assay development), Parsortix platform instrument sales to research laboratories, and partnership/managed-services revenue from Master Services Agreements with pharmaceutical and diagnostic partners.
In 2025 the company underwent a major strategic reset, reducing headcount by approximately 60% (from 110 to 39-44 employees), consolidating to a single Guildford facility, and pivoting from a standalone pharma services model to a partnership-led commercial strategy. FY2025 revenue was £1.4 million (down 52% year-over-year), with a £19.2M operating loss including £7.7M of restructuring charges. The company holds ISO 13485:2016, SOC 2 Type 2, and Cyber Essentials certifications, and previously obtained FDA 510(k) clearance for the Parsortix PC1 system in metastatic breast cancer (May 2022), though it subsequently discontinued its FDA establishment license. Key commercial partnerships include Master Services Agreements with AstraZeneca for clinical trial analytics, and co-marketing agreements with QIAGEN, with additional ecosystem partnerships spanning Myriad Genetics, Roche Diagnostics, and Illumina.
CelLBxHealth firmographics
Firmographics- Name
- CelLBxHealth
- Legal name
- CelLBxHealth plc
- Website
- https://cellbxhealth.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- CelLBxHealth plc is a UK-based liquid biopsy company that develops the Parsortix microfluidic platform for label-free isolation and molecular analysis of circulating tumor cells (CTCs), serving pharmaceutical drug discovery, diagnostic development, and translational research customers through instrument sales and laboratory services.
- Ownership category
- akta.pro rank
CelLBxHealth industry classification
Industry- Product category
- Liquid Biopsy Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH)
- akta.pro secondary industries
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)
Keywords
Where CelLBxHealth is headquartered
LocationHeadquarters
- HQ city
- Guildford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
CelLBxHealth business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Services and Laboratory Services: Service laboratory providing CTC enrichment and analysis services to pharmaceutical companies for drug development, clinical trials, and biomarker discovery. Custom assay development for real-time biomarker assessment.
- Technology Platform Sales: Parsortix platform sales to research laboratories and pharmaceutical partners for in-house CTC processing.
- Partnership and Collaboration Revenue: Revenue from Master Services Agreements with pharmaceutical companies including AstraZeneca for biomarker development work and clinical trial sample analysis.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
CelLBxHealth product offering
Product offeringCore offering
CelLBxHealth develops and commercializes the Parsortix microfluidic platform, a patented label-free system that captures and harvests viable circulating tumor cells (CTCs) and CTC clusters from whole blood based on cell size and deformability. The company complements this core instrument with consumable products (CellKeep Slide, Portrait+ CTC Staining Kit) and a menu of fee-for-service laboratory offerings including CTC enumeration, immunofluorescence biomarker assays (PD-L1, HER2, androgen receptor, DNA damage response), and molecular assays (gene expression, NGS) for pharmaceutical, diagnostic, and academic research customers.
Product overview
CelLBxHealth offers the Parsortix platform as its core product — a next-generation microfluidic system for capturing and harvesting viable circulating tumor cells (CTCs) from whole blood using patented label-free technology. The platform is complemented by the CellKeep Slide (a CTC harvesting consumable that maximizes cell retention for imaging) and the Portrait+ CTC Staining Kit (immunostaining reagents for CTC characterization). The company also provides a comprehensive menu of laboratory services including CTC enumeration, immunofluorescence assays for biomarkers such as PD-L1, HER2, androgen receptor, and DNA damage response (DDR), as well as molecular assays for gene expression profiling and NGS analysis. Together, these products and services enable pharmaceutical partners, diagnostic companies, and researchers to perform real-time CTC profiling for therapy selection, disease monitoring, and drug discovery.
Differentiator
Problem solved
Functional benefit
Brands
- Parsortix: Proprietary microfluidic platform for capturing and harvesting circulating tumor cells (CTCs) from whole blood
- Parsortix PC1
- CellKeep
- Portrait+ CTC Staining Kit
- Portrait Flex
Products and services
- Parsortix Platform Next-generation microfluidic system for enriching and recovering viable circulating tumor cells (CTCs) and CTC clusters from whole blood using patented label-free single-use cassette technology that isolates cells based on size and deformability. Includes the FDA-cleared Parsortix PC1 clinical system for metastatic breast cancer. Sold to research laboratories and pharmaceutical partners for in-house CTC processing and clinical applications.
- CellKeep Slide A unique CTC harvesting consumable that maximizes the retention of circulating tumor cells harvested from blood samples for imaging. Reduces the volume of antibody required to stain harvested CTCs, reducing processing time and costs. Sold as a standalone product compatible with the Parsortix platform.
- Portrait+ CTC Staining Kit Immunostaining kit for circulating tumor cell analysis and characterization, used in combination with the Parsortix platform. Sold as a standalone reagent kit for CTC characterization workflows.
- CelLBxHealth Laboratory Services Fee-for-service laboratory offering providing custom assay development, CTC enrichment, enumeration, and downstream molecular analysis. Includes the Portrait Flex immunofluorescence service for CTC enumeration and characterization; DNA Damage Response (DDR) immunofluorescence assay service; PD-L1 detection service; HER2 assessment service; androgen receptor detection service; and Molecular Assays service for gene expression profiling and next-generation sequencing. Sold to pharmaceutical partners, diagnostic companies, and researchers as a contracted service.
Quantifiable outcome
- CTCs detected in up to 77% of glioblastoma patients compared to less than 10% for ctDNA
- +2 more outcomes
Companies that use CelLBxHealth
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles4 records
CelLBxHealth technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
CelLBxHealth partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- AstraZenecacoreMaster Services Agreement making CelLBxHealth a qualified service provider for one of the world's largest pharmaceutical companies. CelLBxHealth supports AstraZeneca's drug discovery and development through CTC-powered analytics of clinical trial samples using its proprietary Parsortix platform. This partnership drove a 30% rally in CelLBxHealth shares and is expected to lead to recurring project work over time.
- QIAGENcoreNon-exclusive collaboration and co-marketing agreement to promote the Parsortix platform and develop CTC-based research projects. Partnership aims to combine CelLBxHealth's CTC technology with QIAGEN's molecular analysis tools for drug development, biomarker discovery, and diagnostic efforts.
- AdventHealthcoreContracting studies with AdventHealth as part of partnership-focused commercial strategy. AdventHealth represents validated partnership for CTC-based clinical research.
- Royal Marsden NHS Foundation TrustcoreContracting studies with Royal Marsden NHS Foundation Trust, one of the UK's leading cancer research hospitals. Validated partnership supporting clinical research applications.
- Myriad GeneticscoreValidated partnership with Myriad Genetics for diagnostic applications of the Parsortix technology platform. Collaboration for molecular diagnostic development.
Scale indicators11 records
Recent moves8 records
Expansion highlights5 records
CelLBxHealth competitors and assessment
Company assessmentDirect peers
- Menarini Silicon Biosystems: Develops the CellSearch system, the historical gold-standard FDA-cleared platform for enumerating circulating tumor cells in blood. Direct CTC-platform competitor to CelLBxHealth's Parsortix system, focused on similar pharma services and clinical diagnostic applications.
- RareCyte: Provides a CTC isolation and analysis platform targeting pharma biomarker research and clinical applications. Direct competitor to CelLBxHealth's Parsortix system in the CTC-based liquid biopsy market, with overlapping pharma-services offerings.
- Epic Sciences: Develops single-cell CTC characterisation technology for therapy selection and monitoring in oncology. Direct competitor to CelLBxHealth in CTC-based liquid biopsy with a similar focus on pharma services and biomarker discovery.
Broad incumbents
- Guardant Health: Leading ctDNA-based liquid biopsy company offering oncology screening, recurrence monitoring, and therapy selection tests. Competes with CelLBxHealth for the same liquid biopsy wallet share but via a different analyte (ctDNA vs CTCs).
- Natera: Specialised in cell-free DNA-based liquid biopsy tests across oncology and reproductive health. Competes with CelLBxHealth in oncology liquid biopsy applications, with a much larger commercial footprint and broader payor coverage.
- Exact Sciences: Major liquid biopsy and molecular diagnostics player with Cologuard and the Oncotype DX franchise, plus emerging oncology liquid biopsy tests. Competes for similar pharma companion diagnostic and cancer detection budgets as CelLBxHealth.
- Bio-Techne: Provides proteomics and liquid-biopsy tools including CTC-related reagents and exosome diagnostics. Sells into overlapping research and pharma-services customers as CelLBxHealth but across a broader life-science tools portfolio.
Others
- QIAGEN: Molecular diagnostics and sample-prep leader, partner of CelLBxHealth for co-marketing Parsortix. Also an indirect competitor in liquid-biopsy sample-prep and downstream analysis workflows, creating a coopetitive relationship.
- Illumina: Sequencing platform leader and CelLBxHealth integration partner. Enabler/ecosystem player for downstream NGS analysis of CTCs harvested by Parsortix, with strategic relevance but not a direct CTC-platform competitor.
- Myriad Genetics: Molecular diagnostics company with which CelLBxHealth has a validated partnership for diagnostic applications of Parsortix. Overlaps in oncology companion diagnostics, but primarily competing via germline and tissue-based molecular tests.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights6 records
Customer concentration
CelLBxHealth social profiles
Digital presenceCelLBxHealth compliance and trust
Trust signalCompliance4 records
CelLBxHealth financial estimates
Financial estimateRevenue estimate
Valuation estimate
CelLBxHealth leadership team
Management profileNumber of profiles
Profiles5 records
CelLBxHealth subsidiaries and ownership
Company hierarchySubsidiaries2 records
CelLBxHealth funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CelLBxHealth M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CelLBxHealth
What does CelLBxHealth do?
CelLBxHealth develops and commercializes the Parsortix microfluidic platform, a patented label-free system that captures and harvests viable circulating tumor cells (CTCs) and CTC clusters from whole blood based on cell size and deformability. The company complements this core instrument with consumable products (CellKeep Slide, Portrait+ CTC Staining Kit) and a menu of fee-for-service laboratory offerings including CTC enumeration, immunofluorescence biomarker assays (PD-L1, HER2, androgen receptor, DNA damage response), and molecular assays (gene expression, NGS) for pharmaceutical, diagnostic, and academic research customers.
Is CelLBxHealth a public or private company?
CelLBxHealth is a public company. It is classified as public and is currently operating.
When was CelLBxHealth founded?
CelLBxHealth was founded in 2006. It employs 101 to 250 people.
Where is CelLBxHealth based?
CelLBxHealth is headquartered in Guildford, United Kingdom, in the Europe region.
How does CelLBxHealth make money?
Three revenue lines are on record. Pharmaceutical Services and Laboratory Services are the primary driver. The others are technology Platform Sales and partnership and Collaboration Revenue.
Who are CelLBxHealth's main competitors?
Direct peers on record are Menarini Silicon Biosystems, RareCyte and Epic Sciences. Broad incumbents are Guardant Health, Natera, Exact Sciences and Bio-Techne. Others are QIAGEN, Illumina and Myriad Genetics.
Does CelLBxHealth have an API?
No public API is recorded for CelLBxHealth.
What industry is CelLBxHealth in?
CelLBxHealth's product category is Liquid Biopsy Diagnostics. Its primary akta.pro industry code is HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 325413 and its SIC code is 2835.